Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat plus oral vinorelbine metronomic chemotherapy in HR+ HER2- advanced breast cancer
ChiCTR2500107234Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entinostat and vinorelbine in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-free survival (PFS). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
entinostatvinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500107234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107234.